About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, February 21st, 2018

The QualityStocks
Daily Stock List


Rocky Mountain High Brands, Inc. (RMHB)

SizzlingStockPicks, WallstreetSurfers, Penny Picks, ProTrader, Winston Small Cap, Fortune Stock Alerts, SmallCapVoice, Promotion Stock Secrets, PennyPickAlerts, and Damn Good Penny Picks reported previously on Rocky Mountain High Brands, Inc. (RMHB), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Rocky Mountain High Brands, Inc. is a consumer goods enterprise listed on the OTCQB. The Company’s specialty is brand development of health conscious, hemp-infused, food and beverage products and naturally high alkaline water. Rocky Mountain High Brands has now launched its naturally high alkaline spring water, Eagle Spirit Spring Water. Rocky Mountain High Brands is based in Dallas, Texas.

Currently, the Company markets a lineup of four naturally flavored hemp-infused beverages. These are Citrus Energy, Black Tea, Mango Energy and Lemonade. Rocky Mountain High Brands also markets a low-calorie Coconut Lime Energy drink. Furthermore it offers hemp-infused 2 oz. Mango Energy Shots and Mixed Berry Energy Shots.

The Company utilizes a hybrid distribution model. This model leverages distribution contacts and brokers, and direct relationships with wholesalers and retailers to expand strategically into new markets.

Rocky Mountain High Brands involves in sales and distribution via online retailers. At present, the Company distributes its products to an array of retail locations, from grocery to convenience to warehouse stores, across the U.S.

Rocky Mountain High Brands has launched its robust GPS based geofencing software advertising system in the Los Angeles, California market. Geofencing is the practice of employing Global Positioning (GPS) or radio frequency identification (RFID) to define a geographic boundary.

The design of the software package is to interface with mobile devices when a consumer is within proximity of a Rocky Mountain High retailer. The Company’s geofencing software package underwent development by the Beasley Broadcast Group's (BBGI) Digital Marketing Solutions division.

In October 2017, Rocky Mountain High Brands announced that its subsidiary, Rocky Mountain High Water Company, LLC, has a non-gaming vendor registration license with Osage Casinos, the gaming enterprise of the Osage Tribe, to sell its Eagle Spirit Spring Water in their retail establishments. Under this license, Eagle Spirit Spring Water is now selling in this market.

Rocky Mountain High Brands is expanding its product line this year to include CBD-infused waters and functional beverages, hemp and CBD-infused foods, a skin care line and nutraceuticals both containing CBD.

Last week, Rocky Mountain High Brands announced that its new, pioneering hemp-derived CBD-infused product line, HEMPd, led by its flagship CBD-infused waters, will launch next month. HEMPd is a diverse hemp-based health and wellness line. HEMPd is formulated from Full Plant CBD. It contains a non-detectable level of 0.00 percent THC, and is derived from organically grown Colorado hemp.

In addition, last week, Rocky Mountain High Brands announced an update from its Chairman, President & Chief Executive Officer, Mr. Michael Welch, on the Company’s Master Manufacturing Agreement with CBD Alimentos SA de CV (Client).

Mr. Welch stated, “In January, we amended the agreement with our Client at their request to switch from our Rocky Mountain High functional beverages with hemp seed extract to a new formulation of our Rocky Mountain High functional beverages with water soluble cannabidiol (CBD), containing a non-detectable level of 0.00 percent THC (the compound that creates a ‘high’)... Rocky Mountain High Brands will be one of the first companies to infuse a functional beverage with CBD in a can, which affirms our trailblazer status…”

Rocky Mountain High Brands, Inc. (RMHB), closed Wednesday's trading session at $0.01785, up 2.00%, on 35,915,919 volume with 438 trades. The average volume for the last 60 days is 31,133,360 and the stock's 52-week low/high is $0.0053/$0.153.

AfterMaster, Inc. (AFTM)

Wall Street Mover, Equities.com, and TopPennyStockMovers reported earlier on AfterMaster, Inc. (AFTM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AfterMaster, Inc. is an industry leading audio technology business. AfterMaster is a cutting-edge audio technology originally developed for the mastering, re-mastering, and processing of audio through AfterMaster HD Audio Labs, Inc. The Company’s executive team includes music and audio technology leaders Justin Timberlake, Rodney "Darkchild" Jerkins, Pete Doell, Andrew Wuepper, Shelly Yakus, and Larry Ryckman. AfterMaster has its corporate office in Hollywood, California.

AfterMaster delivers a first-rate clarity, depth, and fullness to audio recordings. It does so while delivering a substantial increase in volume without increased distortion or loss of dynamic range. The technology has been used by many top musicians looking to create a fuller and richer sound quality than otherwise available in digital audio.

ProMaster HD is AfterMaster’s online audio mastering service. The integration of ProMaster HD enables Adobe Audition CC users’ to straight away master their original work directly within Adobe Creative Cloud®. ProMaster HD instils the clearest, deepest sound quality into any recording. This raises that audio to a studio remastered sound experience.

AfterMaster has its new AfterMaster Pro. This is the world's first personal re-mastering device. The AfterMaster Pro masters and re-masters inconsistent sound in real-time. AfterMaster Pro is easily installed via HDMI cables between any TV and the A/V source (cable or satellite box, and more).

Furthermore, the portable device is equipped with a rechargeable battery and 1/8" audio ports. Thus, it can be used on-the-go to considerably improve the audio of smartphones, tablets, computers, as well as any audio-enabled device. AfterMaster Pro is manufactured in the U.S.

AfterMaster announced a partnership in 2016 with independent digital music distribution and publishing administration service, TuneCore. With the agreement, AfterMaster serves as TuneCore's professional mastering service, enabling and empowering users with direct access to award-winning senior mastering engineers in AfterMaster's state-of-the-art facilities.

TuneCore has expanded its partnership with Aftermaster. Since April 2016, Aftermaster has been TuneCore's exclusive professional hands-on custom mastering service, led by renowned mastering engineer, Mr. Pete Doell. The expanded partnership gives TuneCore members’ access to the innovative Promaster by Aftermaster instant mastering service, providing audio mastering of first-class quality at the click of a button, while being affordable.

In November 2017, Aftermaster announced that it entered into a license agreement with headphone manufacturer, Muzik, Inc. This license agreement is for the use of Aftermaster's patented audio remastering and audio enhancement technology.

Aftermaster audio technology is available by way of software or from the Company’s pioneering Digital Signal Processing chip (DSP) developed with ON Semiconductor. Muzik is a technology enterprise. Its commitment is to creating disruptive products with premier hardware and intuitive software.

Last week, Aftermaster announced that it commenced online marketing of its Aftermaster Pro TV audio system. The on-line marketing program is overseen and directed by proven industry professionals who have developed online marketing campaigns for more than150 companies. Thousands of Aftermaster Pro units have already sold in more than 65 nations.

AfterMaster, Inc. (AFTM), closed Wednesday's trading session at $0.08, up 43.11%, on 578,597 volume with 23 trades. The average volume for the last 60 days is 95,604 and the stock's 52-week low/high is $0.035/$0.45.

DSG Global, Inc. (DSGT)

Epic Stock Picks, StockHideout, Stock Preacher, Penny Stocks Finder, SuperStockTips, Penny Stock Craze, SMS Penny Picks, eliteotc, WININGOTC, Wall Street Beauties, StockRockandRoll, The Observer, OTC Markets, PennyStockLocks, ResearchOTC, InvestorSoup, and Beacon Equity Research reported previously on DSG Global, Inc. (DSGT), and we report on the Company today, here at the QualityStocks Daily Newsletter.

DSG Global, Inc. is a technology development company whose shares trade on the OTCQB. The Company engages in the design, manufacture, and marketing of fleet management solutions for the golf industry, and also commercial, government, and military applications worldwide. DSG Global has historically concentrated on the golf industry. It has grown to become a leader in the Fleet Management category in the golf industry. DSG Global is based in Surrey, British Columbia.

The Company provides patented electronic tracking systems and fleet management solutions to golf courses. These allow for remote management of the course's fleet of golf carts, turf equipment, as well as utility vehicles. DSG is best known for its advanced GPS TAG System for golf cart and turf equipment fleet management.

DSG Global’s technology is installed in more than 10,000 vehicles on golf courses globally. The Company has an installed base of daily-fee and resort golf courses. Its cart-mounted Touch® display screens seamlessly deliver banner advertisements and full-motion videos while on the golf course.

Fundamentally, golf course operators manage their fleet of golf carts, turf equipment, and utility vehicles remotely, using DSG Global’s SaaS (Software as a Service) technology and advanced GPS hardware. DSG has acquired Impact Tournament Solutions, along with Impact’s team of experts, to run the Tournament Solutions Division of DSG Global.

DSG Global is currently branching into several new streams of revenue via programmatic advertising, licensing, and distribution. Additionally, the Company is expanding into Commercial Fleet Management and Agricultural applications. It realized record European sales in 2017 because of new installation contracts with top rated European Golf Management businesses. Furthermore, DSG Global is expanding into Raptor Single Rider Golf Car and 100E Fully Loaded Mullen Golf Cars, 2 and 4 seaters and Agricultural applications.

DSG Global has officially partnered with golf course video flyover company, STEADY MOTION. This is to bring the best interactive flyover videos to the golf sports industry. These flyover videos include professional, broadcast television quality audio narration, advanced color correction, and interactive course tours ready to be displayed on the DSG TOUCH screens and on golf course web portals.

Last month, DSG Global announced that it is introducing to the global market the first ever Infinity 12" High Definition display. This display is equipped with streaming music, video, Bluetooth, stock market and sports scores, and the top-graded flyovers in the nation, credit card tap availability, dual speakers and Programmatic Advertising.

Furthermore, last month, DSG Global announced that it has taken first steps to move towards exploring potential use cases, which it has identified for blockchain and its related technologies to be applied to the golf industry.

Mr. Robert Silzer, DSG Global’s Chief Executive Officer, stated, "Blockchain will definitely change the golf industry and DSG plans to play a leading role to bring this change to fruition. I believe this technology will revitalize the golf industry. It can build a new bridge between golf and the millennials and raise new enthusiasm for the sport. It can release tremendous value that is currently untapped."

DSG Global, Inc. (DSGT), closed Wednesday's trading session at $0.00158, up 5.33%, on 111,032,158 volume with 211 trades. The average volume for the last 60 days is 16,404,279 and the stock's 52-week low/high is $0.0013/$0.53.

BioCorRx, Inc. (BICX)

Equity Observer, SmallCapVoice, Value Penny Stocks, MassiveStockProfits, BUYINS.NET, OTPicks, Damn Good Penny Picks, Penny Stock Newsletter, PREPUMP STOCKS, Penny Picks, and PennyStocks24 reported earlier on BioCorRx, Inc. (BICX), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, BioCorRx, Inc. is a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. It provides a unique approach to the treatment of substance abuse addiction and has its BioCorRx® Recovery Program. The BioCorRx® Recovery Program is a non-addictive, medication-assisted treatment (MAT) program. BioCorRx’s concentration is on improving the quality of life for recovering addicts. BioCorRx is based in Anaheim, California.

The BioCorRx® Recovery Program comprises two main components. The first component consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist, which can substantially decrease physical cravings for alcohol and opioids.

The second component is a one-on-one proprietary counseling program. It is particularly tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatments.

In addition, the Company has expanded the support structure to include 12 months of a peer-support system using trained recovery specialists. Moreover, BioCorRx is developing a patent pending injectable form of naltrexone.

BioCorRx also has a research and development (R&D) subsidiary, BioCorRx Pharmaceuticals. Currently, this subsidiary is developing a new injectable naltrexone technology (BICX101) via a partnership with TheraKine Ltd.

BioCorRx’s plan is to seek Food and Drug Administration (FDA) approval for BICX101 and/or its naltrexone implant product(s). BICX101 is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism.

Last month, BioCorRx announced a pilot for the BioCorRx® Recovery Program in collaboration with the One Day at a Time Program (ODAAT). This is a program funded by the City of Philadelphia and State of Pennsylvania.

This will be a paid demonstration pilot in which the BioCorRx Recovery Program will be utilized to treat a number of individuals suffering from opioid and alcohol use disorders. The ODAAT program assists greater than 56,000 residents of Philadelphia.

Earlier this month, BioCorRx announced that following the pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA), and based on the FDA’s responses to BioCorRx’s development plan for BICX102, it has extended Dr. Balbir S. Brar’s agreement as VP of Drug Development for the BioCorRx Pharmaceuticals subsidiary for an additional one year period.

Dr. Brar has more than 25 years of experience in drug and device development. This includes international regulatory submissions for greater than 50 INDs, 510(k)s and 505(b)(2)s, and also approval of 8 NDAs for drugs now in the marketplace.

Last week, BioCorRx announced the results of its pre-IND meeting with the FDA. The FDA judged the 505(b)(2) pathway as an acceptable route for approval for BICX102. The 505(b)(2) pathway is intended to provide an abbreviated route to approval with less study requirements than traditional applications. BICX102 is a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders.

BioCorRx, Inc. (BICX), closed Wednesday's trading session at $0.1396, down 6.93%, on 922,434 volume with 92 trades. The average volume for the last 60 days is 785,839 and the stock's 52-week low/high is $0.0426/$0.34.

Envision Solar International, Inc. (EVSI)

SmarTrend Newsletters, OTCJournal, Greenbackers, RedChip, FeedBlitz, Hotstocked, Stock News Now, SmallCapVoice, and Stockwire reported on Envision Solar International, Inc. (EVSI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Envision Solar International, Inc. is the leading renewably energized EV charging, outdoor media and energy security products company. It is a developer of solar products and proprietary technology solutions. The Company designs, manufactures, and deploys unique, renewably energized, EV charging and media and branding systems. Envision Solar International is OTCQB-listed and is based in San Diego, California.

The Company’s products include the patented EV ARC™ and Solar Tree® product lines. All of Envision Solar’s products can be enhanced with EnvisionTrak™ patented solar tracking, ARC Technology™ energy storage, SunCharge™ Electric Vehicle Charging Stations, and digital advertising packages.

Envision Solar has designed and incorporated EnvisionTrak, its proprietary and patented tracking solution, to the Solar Tree structure. The Company has deployed its latest generation of Solar Tree products, the Solar Tree HVLC (High Value, Low Cost) collection.

The new Solar Tree product incorporates its latest engineering and fabrication improvements. Its Solar Tree® structure works as a billboard for a company’s green credentials. This is while producing clean energy and improving the aesthetics of any parking lot.

In addition, Envision Solar has developed the abovementioned EV ARC™. The Company has observed that the EV ARC™ (Electric Vehicle Autonomous Renewable Charger) can solve numerous problems associated with electric vehicle charging infrastructure deployments.

The EV ARC™ fits inside a parking space. It produces enough clean, solar electricity to power up to 225 miles of EV driving in a day.

At the beginning of February, Envision Solar International announced that its new EV-Standard™ product is currently patent pending and in advanced-stage product development preparing for commercialization in Q2 2018.

Envision Solar International Chief Executive Officer, Mr Desmond Wheatley, said, "Our new EV-Standard combines everything we have learned in a mass-market, curbside solution. Many Americans cannot charge their EVs at home and cities need a meaningful and economically viable curbside charging solution. EV-Standard is it. The big city customers I've shared this with view it as a potential game changer."

The EV-Standard is a fully integrated lamp standard and EV charging product. It combines renewable energy, a grid connection, and energy storage to provide a meaningful, on-street, Level II EV charging experience for the millions of Americans who cannot charge at home or at work.

Recently, Envision Solar International announced unaudited Revenue results for January 2018. In January, the Company attained monthly Revenue of $2 million. This represents the highest monthly revenue in Envision’s history. Revenue was realized via the delivery of its EV ARC™ products to government customers.

Envision Solar International, Inc. (EVSI), closed Wednesday's trading session at $0.24, down 2.44%, on 42,658 volume with 24 trades. The average volume for the last 60 days is 99,575 and the stock's 52-week low/high is $0.09/$0.2916.

Northwest Biotherapeutics, Inc. (NWBO)

Streetwise Reports, OTCPicks, FeedBlitz, AllPennyStocks, The Street, Marketbeat, Promotion Stock Secrets, RedChip, Wall Street Corner, BUYINS.NET, PureActionStocks, Pennybuster, WealthMakers, Wealthpire, CoolPennyStocks, StreetInsider, StockPicksNYC, INO Market Report, InvestorPlace, BullRally, and SmallCapVoice reported earlier on Northwest Biotherapeutics, Inc. (NWBO), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Northwest Biotherapeutics, Inc. is a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers. In the U.S. and Europe, the Company’s focus is on developing personalized immunotherapy products, on a cost-effective basis, designed to treat cancers more effectively than existing treatments. This is without toxicities of the kind associated with chemotherapies. Northwest Biotherapeutics has its headquarters in Bethesda, Maryland. The Company lists on the OTC Markets Group’s OTCQB.

Northwest Biotherapeutics’ lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). This trial has completed its enrolment.

The Company has an extensive platform technology for DCVax dendritic cell-based vaccines. It is working to move ahead with manifold clinical programs, involving DCVax-L and DCVax-Direct.

Northwest Biotherapeutics’ is pursuing completion of the present Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer and pursuing Phase II combination trials of DCVax-L and checkpoint inhibitor drugs. This includes the Phase II trial of DCVax-L and Pembrolizumab (Keytruda) for colon cancer, which was earlier announced.

In addition, the Company earlier received clearance from the Food and Drug Administration (FDA) for a 612-patient Phase III trial in prostate cancer. The Company received approval in Germany of a five-year Hospital Exemption for the treatment of all gliomas (primary brain cancers) outside the clinical trial.

In addition, Northwest Biotherapeutics is pursuing a Phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers. It has completed the 40-patient Phase I portion of the trial. It is preparing the Phase II portion. It earlier conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer in association with the University of Pennsylvania.

Yesterday, Northwest Biotherapeutics announced that the Company congratulated Cognate BioServices on the Management Buyout of Cognate supported by international institutional investors, which Cognate announced yesterday. Cognate is the contract manufacturer of Northwest Biotherapeutics’ DCVax® products.

Northwest Biotherapeutics’ product candidates also include DCVax-Prostate. The design of this product is purposely for late stage, hormone independent prostate cancer.

The Company has developed a DCVax product line using a particular proprietary antigen — PSMA (Prostate Specific Membrane Antigen). It is found on essentially all late stage (hormone independent) prostate cancer. The PSMA is produced via recombinant manufacturing methods. It is subsequently combined with the fresh, personalized dendritic cells to make DCVax-Prostate.

Northwest Biotherapeutics, Inc. (NWBO), closed Wednesday's trading session at $0.3176, down 1.37%, on 1,157,540 volume with 199 trades. The average volume for the last 60 days is 1,501,503 and the stock's 52-week low/high is $0.14/$0.43.

NRG Metals, Inc. (NRGMF)

Stockhouse, The Street, MarketWatch, Barchart, and 4-Traders reported earlier on NRG Metals, Inc. (NRGMF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

NRG Metals, Inc. is a Junior Canadian Exploration Company whose shares trade on the OTC Markets Group’s OTCQB. It searches for brine-based lithium targets in Argentina, Bolivia, and Chile. The Company has positioned itself for rapid growth in the brines of South America. NRG Metals is operating in miner-friendly jurisdictions with premier infrastructure, targeting battery-grade lithium and other forms of metal. NRG Metals has its head office in Vancouver British Columbia.

The Company’s objective is to quickly enter the lithium market via developing technically uncomplicated, limited environmental footprint projects in Argentina. The Hombre Muerto North Project in Argentina is in a region of lithium production and development. The Salar Escondido Project in Argentina is a drill ready, fully permitted, 29,000 hectare claim block. It represents an exploration opportunity to make a significant new lithium discovery.

The Salar Escondido Project is in Catamarca Province, 40km south of Antofagasta de la Sierra. NRG Metals controls a dominant portion of the basin with 29,192 hectares under option. Surface sampling in fresh water zones returned anomalous Li values up to 50ppm and high carbonate values. Preliminary interpretation indicates four distinct zones.

The Salar Escondido Project area is strategically positioned within the Lithium Triangle, in close proximity to one of the largest known lithium deposits in Argentina, and within the Puna Region. This area is an elevated plateau, which lies on the eastern side of the Andes Mountains. This area contains a number of highly mineralized salars. This includes the lithium producing salars Hombre Muerto.

NRG Metals’ concentration will be on identifying and establishing a project with the intent of producing an industrial grade lithium product. The Hombre Muerto North Project is a 3,297 Hectare claim package comprising six concessions in Salta Province. Twenty surface samples collected in 2016-2017 range from 48 to 1,064 mg/L Li, averaging 587 mg/L Li, with seven samples over 800 mg/Li.

The Company has applied for permits that include exploration test wells, pumping well tests, as well as evaporation test pond construction. The property package comprises the Alba Sabrina, Tramo, Natalia Maria, Gaston Enrique, Viamonte, and Norma Edit concessions.

This past October, NRG Metals announced that it entered into a Letter of Intent (LOI) with Chengdu Chemphys Chemical Industry Co., Ltd. (Chemphys) in Chengdu, China, pertaining to the further exploration and development of the Hombre Muerto North Lithium Project (HMNLP). Additionally, the LOI includes a Lithium Offtake Sales Agreement and various other terms.

Chemphys specializes in the production of high purity (99.99 percent) Lithium Carbonate and battery grade Lithium Hydroxide. These are for the manufacturing of cathode materials and electrolytes of lithium ion batteries.

In November, NRG Metals announced that, further to its news release of October 17, 2017, it completed various agreements to give effect to its strategic alliance with Chemphys. This is to advance the exploration and development of the Company's Hombre Muerto North Lithium Project (HMNLP).

In December, NRG Metals announced the discovery of lithium at the Salar Escondido Lithium Project. Consistent with NRG’s geophysical data and geological model, the target zone of sediments saturated with brine that could contain lithium was intersected. The Company stated that initial lithium values from near the top of the brine are very encouraging.

Last month, NRG Metals announced the results of a recent sampling program at its 3,237 hectare HMNLP in Salta Province, Argentina.

Mr. Jose de Castro, NRG Metals’ Chief Operating Officer, said, "We are delighted by the high lithium values and the favorable low Mg/Li ratios at Hombre Muerto Norte. NRG recently obtained permits from the provincial government of Salta for drilling and construction of evaporation test ponds, and the Company expects to award a drilling contract and commence construction of the test ponds shortly."

NRG Metals, Inc. (NRGMF), closed Wednesday's trading session at $0.20437, up 0.63%, on 259,941 volume with 62 trades. The average volume for the last 60 days is 550,655 and the stock's 52-week low/high is $0.07/$0.4939.

CareView Communications, Inc. (CRVW)

Tiny Gems, BabyBulls, Stock Stars, MonsterStocksPick, FeedBlitz, Real Pennies, PennyTrader Publisher, Wall Street Resources, and MissionIR reported previously on CareView Communications, Inc. (CRVW), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

CareView Communications, Inc. is an information technology (IT) provider to the healthcare industry. It provides the next generation of patient care via its leading-edge data and patient monitoring system. The system connects patients, families, and healthcare professionals (the CareView System®). The CareView System can help a hospital reduce sitter costs, patient falls and injuries, manage patient flow, improve internal communications, and consolidate vendors. CareView Communications is based in Lewisville, Texas.

CareView’s goal is to be the leading provider of products and on-demand application services for the healthcare industry. This is through specializing in bedside video monitoring, archiving and patient care documentation systems and patient entertainment services. The Company’s proprietary, high-speed data network system may be installed throughout a healthcare facility to provide the facility with recurring revenue and infrastructure for future applications.

The CareView System allows for close observation of high-risk patients from manifold locations. This is to lessen sitter costs and manage staffing resources more efficiently. In addition, the CareView Connect® mobile application provides patient monitoring and critical communication tools from an existing Wi-Fi Android or iOS device.

The CareView System is HIPAA-compliant (Health Insurance Portability and Accountability Act) and secure. The System does not record anything. Moreover, it can include consent processes and privacy options.

Regarding hospital benefits, the CareView System enables patients to watch first-run movies and access high-speed internet. The result of this is increased patient satisfaction.

The CareView System employs an infrared camera in patient rooms to deliver real-time visual monitoring around the clock. The Company installs its equipment in healthcare facilities at no charge. It then produces revenue from subscriptions to its set of products and services. These are priced as a bundled service.

In 2017, CareView Communications executed an agreement with Dish Network, LLC, to become a Private Cable Operator (PCO). This agreement enables the Company to provide television network services via Dish Network as part of its full suite of products and services offered by way of its CareView System®.

The CareView system is installed in thousands of beds in greater than 100 hospitals around the U.S. The Company’s cost effective platform and setup capitalizes on fixed cameras in the room. The system is username and password protected. It is accessible to qualified users on site only.

CareView Communications, Inc. (CRVW), closed Wednesday's trading session at $0.0299, up 18.65%, on 13,750 volume with 2 trades. The average volume for the last 60 days is 96,784 and the stock's 52-week low/high is $0.02/$0.215.

Alacer Gold Corp. (ALIAF)

MarketWatch, TradingView, Investing, Silverstocker, InvestorPlace, GoldStockData, NorthernMiner, 4-Traders, Investopedia, OTC Markets, The Street, MiningFeeds, Information Vine, and Penny Stock Tweets reported on Alacer Gold Corp. (ALIAF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Alacer Gold Corp. is a foremost intermediate gold mining company headquartered in Denver, Colorado. The Company has an 80 percent interest in the world-class Çöpler Gold Mine in Turkey operated by Anagold Madencilik Sanayi ve Ticaret A.S. The remaining 20 percent is owned by Lidya Madencilik Sanayi ve Ticaret A.S. Alacer Gold is pursuing initiatives to enhance value beyond the present mine plan. Alacer Gold’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s main emphasis is to take advantage of its cornerstone Çöpler Mine and strong balance sheet to maximize portfolio value, maximize free cash flow, and minimize project risk. The Çöpler Mine is located in east-central Turkey in the Erzincan Province.

The Çöpler Gold Mine produced 119,036 ounces of gold during 2016. Çöpler has considerable Probable Reserves of 4 million recoverable ounces and Measured and Indicated Resources of 6 million ounces of contained gold. These provide the basis for Çöpler’s 20 year mine life.

At present, the Mine is an open-pit, heap-leach operation producing low-cost gold from oxide ore. Over the life of the present heap-leach project, roughly 76 percent of the gold contained in the oxide ore is expected to be recovered.

In May of 2016, Alacer Gold’s Board of Directors approved full construction of the Sulfide Project at the Çöpler Gold Mine, with first gold pour expected in Q3 of 2018. The Çöpler orebody contains refractory sulfide ore. This necessitates a different processing solution than heap-leaching to extract the gold.

The Sulfide Project construction is over 75 percent complete, under budget, and on course for first gold production in Q3 2018. The expectation is that the Sulfide Project will deliver long-term growth with strong financial returns and adds 20 years of production at the Çöpler Gold Mine. The Sulfide Project will bring Çöpler’s remaining life-of-mine gold production to greater than 2 million ounces at All-in Sustaining Costs averaging $645 per ounce.

This week, Alacer Gold announced full-year 2017 production results, unaudited full-year cost results, and 2018 production and cost guidance.

Mr. Rod Antal, President and Chief Executive Officer of Alacer Gold, stated, “I am pleased to report that we produced 168,1631 ounces of gold at unaudited All-in Sustaining Costs (AISC) of $685 per ounce in 2017, meeting our original production and beating AISC cost guidance for the year. The production initiatives generated through our operational excellence program were very successful, delivering 64,542 ounces in the fourth quarter, making it the strongest quarter of the year… 2018 production guidance is 120,000 to 190,000 ounces from Çöpler oxides and sulfides. We also expect initial mining at a new oxide deposit, Çakmaktepe, later this year.”

Alacer Gold Corp. (ALIAF), closed Wednesday's trading session at $1.7454, up 0.89%, on 1,100 volume with 3 trades. The average volume for the last 60 days is 20,545 and the stock's 52-week low/high is $1.42/$2.33.

eWellness Healthcare Corp. (EWLL)

StockHideout and Penny Stock Prodigy reported previously on eWellness Healthcare Corp. (EWLL), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, eWellness Healthcare Corp. develops a telemedicine platform. This platform is for providing Distance Monitored Physical Therapy programs. These programs are for pre-diabetic, cardiac, and health challenged patients through contracted physician practices and healthcare systems. eWellness Healthcare is headquartered in Culver City, California.

The Company has launched PHZIO. The design of this Physical Therapy Telemedicine platform is to extend and scale a physician’s practice. eWellness Healthcare is the first physical therapy telemedicine company to provide insurance reimbursable real-time distance monitored treatments.

eWellness Healthcare’s business model is to license the PHZIO platform to any Physical Therapy (PT) clinic in the U.S. and/or have large-scale employers use its PHZIO platform as a completely PT monitored corporate wellness program. eWellness Healthcare’s PHZIO extends a traditional practice online.

The main features of the PHZIO platform include video treatment protocols, real-time patient monitoring, patient induction forms, a patient video journal, and post treatment evaluations. Furthermore, main features include integrated billing, patient metrics, as well as user administration & customization.

PHZIO also scales a practice’s billable rates. In addition, it provides tools to make growing a business easier.

Regarding the Patient Dashboard, the PHZIO Dashboard enables clients to login securely to access prescribed treatment protocols. PHZIO is user-friendly and highly reliable to operate for PT and Patient. It is also a complete on-line PT telemedicine intervention system.

Evolution Physical Therapy has added eWellness Healthcare's Telehealth PT Services at its four clinical locations in Los Angeles, California. This includes Culver City, Playa Vista, Beverly Hills, and Brentwood. Mr. Darwin Fogt, Chief Executive Officer of eWellness Healthcare, owns Evolution Physical Therapy.

This past October, eWellness Healthcare announced the launch of its new patient lead generation platform, LeadRemedy.com. Lead Remedy increases a Practices’ social networks reach through tapping in to the employees of the practice and their social circles.

Each week, relevant physical therapy content is sent to practice employees to review and share. Upon a prospective patient viewing the content, the Practice’s brand is always present; the patient can book an evaluation appointment directly from the viewing page.

Mr. Darwin Fogt, eWellness Healthcare Chief Executive Officer, stated, “Physical Therapy Clinics are continually seeking to attract new patients in order to grow and maintain the success of their Practices. Traditionally, this is done through doctor referrals, word of mouth or advertising. Few practices use social media content to attract new patients. Typically, this lack of social media presence is due to the Practice Owners not having the capacity or capability to produce the content needed to be relevant to prospective patients. Practices that sign up for our Lead Remedy Service solve this outreach problem”.

eWellness Healthcare Corp. (EWLL), closed Wednesday's trading session at $0.105, up 5.00%, on 573,643 volume with 46 trades. The average volume for the last 60 days is 250,310 and the stock's 52-week low/high is $0.058/$0.1995.


The QualityStocks
Company Corner


Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P)

The QualityStocks Daily Newsletter would like to spotlight Liberty Leaf Holdings Ltd. (LIBFF). Today, Liberty Leaf Holdings Ltd. closed trading at $0.3839, off by 7.49%, on 33,066 volume with 19 trades. The stock’s average daily volume over the past 60 days is 200,448, and its 52-week low/high is $0.0091/$0.8074.

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF), is a publicly traded Canadian-based company with strategic investments in businesses that are established, revenue- producing players in the medicinal and recreational cannabis market. Liberty Leaf’s focus is to build and support a diversified portfolio of cannabis-sector businesses, including those involved in the cultivation and processing of legal medicinal and recreational cannabis, value-added CBD/THC pet products, and supply-chain products for this dynamic and fast-growing sector. Liberty Leaf provides funding, management, HR resources and marketing expertise to help companies thrive and accelerate growth.

Liberty Leaf’s leading investments to date include:

  • North Road Ventures – An emerging end-to-end distributor of cultivated and manufactured cannabis products to licensed legal retailers. North Road has updated its application for an Access to Cannabis for Medical Purposes Regulations (ACMPR) license to be distribution/sales-focused, making the company unique in the crowded field of other cultivation-based applicants. This forward-thinking initiative will help fulfill the anticipated increase in Canada’s recreational cannabis space once legalization takes effect in mid-2018. The submission includes a boost in product-vault capacity that will result in a five-fold increase in products available for distribution. Cannabidiol (CBD)-oil products are expected to account for 50 percent or more of projected sales.
  • Just Kush Enterprises – Liberty Leaf holds a 60 percent interest in Just Kush, a cultivator of premium, proprietary cannabis strains selected for different levels of CBDs and THCs. Just Kush’s cultivation facility is located near Oliver, British Columbia, and it currently controls a facility which holds a Medical Marihuana Access Regulations (MMAR) license. The company is also a late-stage applicant for an ACMPR license (Access to Cannabis for Medical Purposes Regulations), which will enable Just Kush to produce cannabis for the medicinal and recreational market.

Liberty Leaf is also an active partner with the following companies:

  • ESEV R&D – A privately owned, medical marijuana research and development company based in New York with clinical laboratories located in Israel. ESEV R&D, in collaboration with a leading clinical research organization in Israel, has launched a one-of-a-kind service for North American medical cannabis companies to organize and oversee clinical trials seeking to demonstrate the efficacy of medical cannabis products for specific medical conditions. Liberty Leaf has a three-year collaborative agreement with ESEV. Under that agreement, ESEV is researching the efficacy of CBDs in pets, with the 1st formulation trial targeting canine osteoarthritis, a medical condition that includes: hip dysplasia; elbow dysplasia; and hind-knee, also known as stifle, degenerative joint disease (DJD).
  • Blox Labs Inc. – A boutique technology company focused on creating best-in-class smartphone apps and software solutions driven by emerging trends in blockchain, smart contracts and decentralized application technologies. Liberty Leaf and Blox Labs are developing “cannaBLOX,” a blockchain-based smart contract supply chain management platform for the legalized cannabis industry.

The company’s management team is led by President and Director William Rascan who has 25-plus years in the investment brokerage industry, most recently as a partner, senior investment advisor with Northern Securities. Rascan’s business experience ranges from active international trading clients to raising capital for junior mining companies on the TSX Venture Exchange.

Rascan is joined by CFO Jamie Robinson, a chartered accountant who specializes in accounting, auditing, and financial reporting under both IFRS and ASPE. Prior to joining Liberty Leaf, Robinson worked at Deloitte as a manager focused on publicly listed and private company audits, business review, performance enhancement engagements and restructuring proceedings.

Steven Feldman, who has more than 25 years of experience in the capital markets and was part of the original management team of SouthGobi Resources; and Doug Macdonell, a retired RCMP officer and recognized expert in the field of cannabis and cultivation, serve as company directors. Dr. Robert Jackman, who has worked closely with multiple clients in the medical cannabis and Natural and Non-prescription Health Products (NNHP) industries in North America, was recently appointed as scientific project manager/fulfillment.

Liberty Leaf’s advisory board includes international lawyer, writer and speaker Robert W.E. Laurie; Barinder Rasode, who currently serves as CEO of the National Institute for Cannabis Health & Education (NICHE); and Dr. Mary C. Fitzpatrick, B.S., D.V.M., whose primary focus is on helping companion animals live pain free in their senior years. Disclaimer

Liberty Leaf Holdings Ltd. Company Blog

Liberty Leaf Holdings Ltd. News:

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) is “One to Watch”

Liberty Leaf and North Road Ventures Welcome BC Retail Guidelines for Cannabis

Liberty Leaf Appoints Barinder Rasode To Advisory Board

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF). Today, PreveCeutical Medical Inc. closed trading at $0.38, up 58.33%, on 231,381 volume with 111 trades. The stock’s average daily volume over the past 60 days is 8,954, and its 52-week low/high is $0.01/$0.80.

There are inherent metabolic issues in consistent, effective delivery of cannabinoids, and these new pharmaceutical therapeutics require revolutionary techniques of administration. Establishing a new paradigm in cannabinoid drug delivery, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is engineering a unique Sol-gel nose-to-brain delivery platform to provide direct, controlled pharmacological drug release.

PreveCeutical Medical Inc. (PRVCF), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word "PreveCeutical" – a combination of the words "preventive" and "pharmaceutical" – was a precursor to the company's formation and incorporation in October 2015.

The company's first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical's research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical's gene-silencing technology would effectively "turn off" the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical's science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland's (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.'s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company's core. Disclaimer

PreveCeutical Medical Inc. Company Blog

PreveCeutical Medical Inc. News:

A New Breakthrough in Cannabinoid Drug Delivery

NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Aims to Halt Cancerous Tumor Progression Utilizing Scorpion Venom Product

NetworkNewsAudio Announces Audio Press Release (APR) on Drug Delivery Advancements Bring Attractive Investment Opportunities

Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.5304, up 16.16%, on 43,040 volume with 43 trades. The stock’s average daily volume over the past 60 days is 255,753 and its 52-week low/high is $0.22/$0.881.

Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), is pleased to provide an official corporate update on its achievements, related scientific activities and growth strategies for the first quarter of fiscal 2018.

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Veritas Pharma Provides Corporate Update on Q1 2018

Veritas Intends to Complete the 100% Takeover of Cannevert Therapeutics in Q1

Veritas’ Research Arm Cannevert Signs Clinical Research Agreement for Human Studies to Assess its Lead Cannabis Strain for Pain

First Cobalt Corp. (TSX.V:FCC) (OTCQB:FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF). Today, First Cobalt Corp. closed trading at $0.85, up 6.06%, on 552,622 volume with 353 trades. The stock’s average daily volume over the past 60 days is 287,306, and its 52-week low/high is $0.3148/$1.3041.

First Cobalt Corp. (TSX-V: FCC, ASX: FCC, OTCQB: FTSSF) (the "Company") is pleased to announce it has begun drilling in Cobalt North, near the historic Drummond, Kerr and Conisil mines. This new program follows completion of a maiden drill program in Cobalt South that identified three distinct mineralized areas that will require follow up. Also today, NetworkNewsAudio, via NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions for business, announced the online availability of its interview with First Cobalt, a client of NNW focused on creating the largest pure-play cobalt exploration and development company in the world. The interview can be heard at https://www.networknewswire.com/networknewsaudio/first-cobalt-corp-interview/

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

First Cobalt Corp. Company Blog

First Cobalt Corp. News:

First Cobalt Begins Drilling in Cobalt North

NetworkNewsWire Releases Exclusive Audio Interview with First Cobalt Corp.

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF) is “One to Watch”

Medical Cannabis Payment Solutions (REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG). Today, Medical Cannabis Payment Solutions closed trading at $0.044, up 7.06%, on 295,478 volume, with 45 trades. The stock’s average daily volume over the past 60 days is 755,368, and its 52-week low/high is $0.0161/$0.155.

The states’ need and subsequent reliance on marijuana tax revenues pits state rights against federal oversight. This ongoing impasse has created a banking conundrum and an enormous opportunity for Medical Cannabis Payment Solutions (OTC: REFG).

Medical Cannabis Payment Solutions (REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company's state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company's unique "StateSourced" proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven't been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin's cryptocurrency ($Weed) with Medical Cannabis Payment Solutions' StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

"We've completed our transition from development stage to revenue stage," says Roberts. "We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases."

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry. Disclaimer

Medical Cannabis Payment Solutions Company Blog

Medical Cannabis Payment Solutions News:

Medical Cannabis Payment Solutions (REFG) Helps Fill State Coffers

NetworkNewsWire Announces Publication on the Commitment of Medical Cannabis Payment Solutions (REFG) to Regulatory Compliance Ahead of Utah Bill

CannabisNewsBreaks – Medical Cannabis Payment Solutions (REFG) Helps Cannabis Distributors Remain Compliant with Green Platform

Petroteq Energy Inc. (TSX.V:PQE) (OTCQX:PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF). Today, Petroteq Energy Inc. closed trading at $1.1321, up 5.72%, on 12,856 volume with 55 trades. The stock’s average daily volume over the past 60 days is 90,419, and its 52-week low/high is $0.015/$1.8892.

Uber, the peer-to-peer ridesharing company, is perhaps the poster child for what has come to be called the sharing economy. Now, Petroteq Energy Inc. (OTCQX: PQEFF) (TSX.V: PQE) is out to take that sharing concept one step further, in the oil and gas industry, with its PetroBLOQ blockchain platform.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQB: PQEFF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

Petroteq Energy Inc. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, Petroteq Energy Inc. and its mining interests are primed for success.

Petroteq Energy Inc. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

Petroteq Energy Inc. Company Blog

Petroteq Energy Inc. News:

Petroteq Energy’s (TSX.V: PQE) (OTCQX: PQEFF) Blockchain Platform Taking Sharing Economy to Oil & Gas Industry

Petroteq Energy Announces Development of PetroBLOQ Payments

NetworkNewsAudio Announces Audio Press Release (APR) on Innovators Gearing Up to Execute Blockchain-Powered Solutions

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $1.20, up 3.45%, on 20,278 volume with 33 trades. The stock’s average daily volume over the past 60 days is 140,018 and its 52-week low/high is $0.20/$1.75.

SinglePoint, Inc. (OTCQB:SING) is pleased to announce a Letter of Intent (“LOI”) with ORHub, Inc. (OTC:ORHB)  to build-out a blockchain services platform for health care applications. ORHub’s surgical resource management (“SRM”) software is transforming the way hospitals handle operating room data, enabling dramatic reductions in supply chain costs.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

SinglePoint Signs LOI with ORHub to Launch Healthcare Blockchain Initiative

ORHub Launches Healthcare Blockchain Initiative to Expand Data Innovation at Point of Care

NetworkNewsAudio Announces Audio Press Release (APR) on ORHub, Now Funded for Further Market Reach with Revolutionary Software

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.07, off by 3.98%, on 4,840,244 volume with 373 trades. The stock’s average daily volume over the past 60 days is 13,785,701, and its 52-week low/high is $0.0132/$0.415.

Specialized holding company SinglePoint, Inc. (OTCQB: SING) this morning said that it has signed a Letter of Intent (“LOI”) with ORHub, Inc. (OTC: ORHB) to develop a blockchain services platform for health care applications. Per the agreement, ORhub will engage SinglePoint for up to $750,000 in initial development costs.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsBreaks – SinglePoint, Inc. (SING) Inks LOI with ORHub, Inc. (ORHB) to Launch Healthcare Blockchain Platform

NetworkNewsBreaks – ORHub, Inc. (ORHB) Signs LOI with Singlepoint, Inc. (SING); Launches Healthcare Blockchain Initiative

Singlepoint, Inc. (OTCQB: SING) CEO Greg Lambrecht and President Wil Ralston discuss bitcoin and cannabis industries on MoneyTV with Donald Baillargeon, 2/16

Skinvisible, Inc. (SKVI)

The QualityStocks Daily Newsletter would like to spotlight Skinvisible, Inc. (SKVI). Today, Skinvisible, Inc. closed trading at $0.0272, off by 4.23%, on 302,029 volume with 16 trades. The stock’s average daily volume over the past 60 days is 226,779 and its 52-week low/high is $0.02/$0.33.

If history repeats itself, as we are often told, then Skinvisible, Inc.’s (OTCQB: SKVI) proposed deal with Quoin Pharmaceuticals Limited (“Quoin”) could increase shareholder value after execution. In late 2017, the company announced its plan to merge with Quoin, a marriage made in heaven that combines Skinvisible’s virtues as a drug delivery developer with Quoin’s position as a producer of post-surgical pain products that replace or diminish opioid use (http://cnw.fm/Fi2E7).

Skinvisible, Inc. (SKVI) through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible's formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of "gold standard" dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible's patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company's revenue stream.

Independent studies of Invisicare® have shown the following benefits:

  • Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
  • Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
  • Unique formulations are non-drying and provide the ability to control the release of active ingredients.
  • Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin's natural exfoliation process.

Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company's business strategy.

Skinvisible's foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company's first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world's leading cannabis companies. As part of the company's overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible's cannabis products within their territory.

"We are excited about the results we are already seeing just with our hemp-derived CBD products," Howlett says. "Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare."

The Company's business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees. Disclaimer

Skinvisible, Inc. Blog

Skinvisible, Inc. News:

Skinvisible, Inc. (SKVI) Aims to Increase Shareholder Value through Proposed Deal with Quoin

NetworkNewsBreaks – Skinvisible, Inc. (SKVI) DermSafe Hand Sanitizer Stops Influenza A from Spreading

Skinvisible, Inc. (SKVI) Products Can Offer Protection against Highly Contagious Viruses like H3N2

RJD Green Inc. (RJDG)

The QualityStocks Daily Newsletter would like to spotlight RJD Green Inc. (RJDG). Today, RJD Green Inc. closed trading at $0.0194, off by 8.06%, on 8,075,677 volume with 257 trades. The stock’s average daily volume over the past 60 days is 4,837,474, and its 52-week low/high is $0.006/$0.029.

RJD Green Inc. (RJDG) is a holding company with a focus on acquiring and managing assets and companies in three divisions. These initial high-growth enterprise opportunities offer diversity in separate recession resistant markets. The division holdings include:

  • RJD Green Healthcare Services – provides services to reduce cost and enhance management and operational capabilities in the healthcare sector.
  • Earthlinc Environmental Services – provides green environmental services and technologies.
  • Silex Holdings – acquires specialty construction and industrial manufacturing assets.

RJD Green Healthcare Services, through its wholly owned subsidiary IOSOFT Inc., provides proprietary software and IT support for medical billing, healthcare claims adjudication, and electronic payments between healthcare payers and providers. IOSOFT's unique payment technologies and services or software can be integrated with existing systems of healthcare payers such as Blue Cross, Aetna, CIGNA and others. IOSOFT provides targeted offerings for healthcare providers, provider networks, physicians and hospitals, and clearinghouse companies.

Earthlinc Environmental Solutions was formed to bring forward green-applied technologies and offer environmental services with a focus on North America. The division's first acquisition, Animal Waste Management, is launching operations of a patented, fully developed technology for processing waste produced on commercial poultry and hog farms. Development of this technology was supported by the University of Arkansas and the Missouri Department of Natural Resources. This important technology improves the farm's productivity and is competitively priced with the current expense of handling waste removal at these sites.

The company's third division – Silex Holdings Inc. – was formed to acquire and manage high-growth assets and business enterprises in the industrial and construction specialty services sectors. With its first acquisition of Silex Interiors, a manufacturer, distributor and installer of counter tops, cabinets and related kitchen and bath products, the division is poised to expand into major national markets through internal expansion, acquisition and franchising. The company is modeled to operate a minimum of four corporately owned locations with 12 to 18 franchise locations nationwide.

RJD Green seeks to participate as owners, partners or in joint ventures in a wide range of business enterprises. The company's goal of creating a successful, enjoyable business enterprise for its company team and staff, along with its business partners and investors, is paired with the goal of maximizing the business potential of the enterprise by enhancing profits and the quality of the company. Disclaimer

RJD Green Inc. Company Blog

RJD Green Inc. News:

RJD Green, Inc. Announces Earthlinc Environmental Enters Acquisition Discussion

RJD Green Inc. appoints Mr. Jerry Niblett as Chief Operating Officer

RJD Green, Inc. Announces Earthlinc Environmental Services Launches New Division


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(PRVCF) +58.33%


(ANTH) +43.79%


(AFTM) +43.11%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251